Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
25 hedge funds and large institutions have $312K invested in Biolase, Inc. in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
14% more funds holding
Funds holding: 22 → 25 (+3)
79% less capital invested
Capital invested by funds: $1.49M → $312K (-$1.17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$238K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$161K |
| 3 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$91.1K |
| 4 |
Millennium Management
New York
|
+$68.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$26.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$545K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$430K |
| 3 |
Renaissance Technologies
New York
|
-$39K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$16.5K |
| 5 |
VF
Virtu Financial
New York
|
-$2.11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $1 | – | – | – |
|
|
HNB
27
Huntington National Bank
Columbus,
Ohio
| $1 | – | – | – |
|
|
AIC
28
AWM Investment Company
New York
| – | -$545K | -19,386 | Closed |
|
|
29
Renaissance Technologies
New York
| – | -$39K | -1,388 | Closed |
|
|
30
Prudential Financial
Newark,
New Jersey
| – | -$16.5K | -588 | Closed |
|
31
Citigroup
New York
| – | -$561 | -20 | Closed |
|
|
OCM
32
Orion Capital Management
Coronado,
California
| – | -$562 | -20 | Closed |
|
BIOL Hedge Fund Activity: Q2 2023 in Review
25 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q2 2023, worth a combined $312K — down 79% from $1.49M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BIOL positions and 5 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $238K. The largest seller was AWM Investment Company, exiting entirely with an estimated $545K sold.
- 25 institutional investors held Biolase, Inc. (BIOL) as of Q2 2023, up from 22 in Q1 2023.
- Funds reported $312K of Biolase, Inc. stock for Q2 2023, down 79% quarter-over-quarter.
- 8 funds opened new Biolase, Inc. positions in Q2 2023 and 5 closed out, a net change of +3 holders.
- The largest Biolase, Inc. buyer in Q2 2023 was Walleye Capital, an estimated $238K added.
- The largest Biolase, Inc. seller in Q2 2023 was AWM Investment Company, an estimated $545K sold.
Based on aggregated 13F filings for Q2 2023.